Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison

Yoon K Loke, Shiva Pradhan, Jessica Ka-Yan Yeong, Chun Shing Kwok

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)

Abstract

There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared to dabigatran.
Original languageEnglish
Pages (from-to)707–717
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Volume78
Issue number4
Early online date11 Mar 2014
DOIs
Publication statusPublished - Oct 2014

Keywords

  • acute coronary syndrome
  • apixaban
  • dabigatran

Cite this